1,064 results on '"Trent, Jeffrey M"'
Search Results
52. Supplementary Table S1 from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases
53. Tables S1 to S13 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
54. Supplementary Figures and Methods from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases
55. Figure S2 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
56. Figure S3 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
57. Figures S1-3 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
58. Table S2 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
59. Supplementary Legend from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
60. Figure S6 from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
61. Figure S1 from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
62. Data from SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma
63. Supplemental Methods from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
64. Supplementary Figures and Tables from SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma
65. Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
66. Supplementary Methods from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
67. Table S5-6 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition
68. Data from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases
69. Supplementary Figure S3 from Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
70. Supplementary Materials and Methods from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
71. Supplementary Tables 1-3 from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
72. Data from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
73. Supplementary Figure 1 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
74. Supplementary Data 4 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
75. Supplementary Data 3 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
76. Supplementary Figures 1-2 from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
77. Supplementary Data 2 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
78. Supplementary Data 1 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
79. Data from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen
80. AIM1, a Novel Non-Lens Member of the β γ -Crystallin Superfamily, is Associated with the Control of Tumorigenicity in Human Malignant Melanoma
81. Multiple Mechanisms of N-phosphonacetyl-L-aspartate Resistance in Human Cell Lines: Carbamyl-P Synthetase/Aspartate Transcarbamylase/Dihydro-Orotase Gene Amplification is Frequent only when Chromosome 2 is rearranged
82. Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search
83. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2
84. Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer
85. Abstract C039: Influence of patient ancestry on homologous recombination repair deficiency in cancer
86. Abstract A006: Increased germline mutational burden in individuals of African ancestry: Implications for interpretation of tumor mutation burden
87. Cancer Genomics and Evolution
88. Inherited Genetic Changes in Prostate Cancer
89. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients
90. Abstract 2013: Integrated proteomic analysis identifies four distinct subtypes of high-risk neuroblastoma
91. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.
92. Obtaining and Evaluating Gene Expression Profiles with cDNA Microarrays
93. A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research
94. A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma
95. Advancing a clinically relevant perspective of the clonal nature of cancer
96. Use of cDNA Microarrays to Assess DNA Gene Expression Patterns in Cancer
97. Inherited Genetic Variant Predisposes to Aggressive but Not Indolent Prostate Cancer
98. Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma
99. The Gene Topography of Cancer
100. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.